MedTrace Logo

Etravirine Plus 2 Analogs in HIV-infected Patients

NCT01437241 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 175

Last updated 2011-11-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the virological and clinical efficacy of etravirine plus 2 active nucleos(t)ide reverse-transcriptase inhibitors (NRTIs) in HIV-infected patients. Additionally, the safety of these regimens, specially lipid profiles, will be assessed.

Conditions

Sponsors & Collaborators

  • Hospitales Universitarios Virgen del Rocío

    lead OTHER

Principal Investigators

  • Luis F Lopez-Cortes, MD, PhD. · Hospitales Universitarios Virgen del Rocio

  • Francisco Tellez-Perez, MD · Hospital de la Linea de la Concepcion

  • Antonio Vergara-Campos, MD, PhD. · Hospital Universitario de Puerto Real

  • Milagros Garcia-Lazaro, MD · Hospital Universitario Reina Sofia de Cordoba

  • Jose Hernandez-Quero, MD, PhD. · Hospital Universitario San Cecilio

  • Juan Pascuau-Liaño, MD, PhD. · University Hospital Virgen de las Nieves

  • Miguel A Lopez-Ruz, MD, PhD · University Hospital Virgen de las Nieves

  • Mohamed O Mohamed-Balghata, MD · Hospital Universitario Ciudad de Jaén

  • Dr.Javier de la Torre-Lima, MD, PhD · Hospital Costa del Sol

  • Manuel Marquez Solero, MD · Hospital Universitario Virgen de la Victoria

  • Marcial delgado, MD · Hospital Universitario Carlos Haya

  • Fernando Lozano-León, MD, PhD. · Hospital Universitario de Valme

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-07-31
Completion
2011-09-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01437241 on ClinicalTrials.gov